Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working Party
- 1 October 1988
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 70 (2), 177-182
- https://doi.org/10.1111/j.1365-2141.1988.tb02460.x
Abstract
This is an analysis of 509 patients with severe aplastic anaemia (SAA) treated in Europe between 1981 and 1986; 218 patients were treated by allogeneic bone marrow transplantation (BMT) from HLA identical sibling donors and 291 with immunosuppressive therapy (IS) with antilymphocyte globulin (ALG). The overall actuarial survival was 63% after BMT and 61% after IS therapy at 6 years. All patients fulfilled the criteria of SAA; however, most patients with a neutrophil count of 9/l also had infections and haemorrhages. Therefore a further subclassification was defined by pretreatment peripheral blood neutrophil count: very severe aplastic anaemia (vSAA) (9/l neutrophils) and moderately severe aplastic anaemia (mSAA) (0.2-0.5 × 109/l neutrophils). A Cox regression analysis showed that the only significant pre-treatment variables were a low neutrophil count (P= 0.001) and increasing age (P= 0.05). Thus it seemed reasonabie to analyse survival data after combined stratification for neutrophils (vSAA versus mSAA) and age (cut off at 20 years). BMT was superior to IS in patients with vSAA under 20 years of age (64%v. 38%;P= 0.01). IS was superior to BMT in patients with mSAA aged 20 or more (82%v. 62%; P= 0.002). The two treatments gave comparable results in young patients with mSAA (BMT = 58%, IS = 62%; P= 0.1), and in older patients with vSAA (BMT = 44%. IS = 43%; P= 0.06). Overall 75/218 and 87/291 patients, given BMT or IS respectively, died. The major cause of failure in BMT patients was graft rejection (n= 22) or problems associated with graft-versus-host disease. For ALG patients the major problem was persistence of the aplasia with haemorrhage (n= 32) or infections (n= 46). This study indicates that over 60% of patients with SAA can be successfully treated with either BMT or IS. Overall survival does not differ in the two groups, though significant differences emerge after stratification for severity of the aplasia and age.This publication has 14 references indexed in Scilit:
- Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factorsBlood, 1986
- Antithoracic duct lymphocyte globulin therapy of severe aplastic anemiaBlood, 1983
- Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemiaBlood, 1983
- Antithymocyte Globulin Treatment in Patients with Aplastic AnemiaNew England Journal of Medicine, 1983
- Anti‐Thymocyte Globulin Treatment for Aplastic AnemiaScandinavian Journal of Haematology, 1982
- USE OF CYCLOSPORIN A IN ALLOGENEIC BONE MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANEMIATransplantation, 1982
- TREATMENT OF SEVERE APLASTIC-ANEMIA WITH ANTI-LYMPHOCYTE GLOBULIN AND ANDROGENS1978
- TREATMENT OF APLASTIC ANÆMIA BY ANTILYMPHOCYTE GLOBULIN WITH AND WITHOUT ALLOGENEIC BONE-MARROW INFUSIONSThe Lancet, 1977
- Meaningful clinical classification of therapeutic responses to anticancer drugsClinical Pharmacology & Therapeutics, 1961
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958